[1]Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study[J]. Lancet, 2018, 391:1285-1300. [2]Chung JR, Kim SS, Konder RJ. et al. Interim estimates of 2021-22 seasonal influenza vaccine effectiveness-United States, February 2022[J]. MMWR Morb Mortal Wkly Rep, 2022,71:365-370. [3]Yang LP. Recombinant trivalent influenza vaccine (Flublok®): a review of its use in the prevention of seasonal influenza in adults[J]. Drugs, 2013, 73:1357-1366. [4]Richards KA, Moritzky S, Shannon I, et al. Recombinant HA-based vaccine outperforms split and subunit vaccines in elicitation of influenza-specific CD4+T cells and CD4+T cell-dependent antibody responses in humans[J]. Npj Vaccines, 2020, 5:1-10. [5]Deng YC, Liu Q, Huang Q, et al. Molecular docking of human-like receptor to hemagglutinins of Avian Influenza A viruses[J]. ACTA Phys-Chim Sin, 2017, 33:633-641. [6]Wang K, Holtz KM, Anderson K, et al. Expression and purification of an influenza hemagglutinin-one step closer to a recombinant protein-based influenza vaccine[J]. Vaccine, 2006, 24:2176-2185. [7]Bosch BJ, Bodewes R, de Vries RP, et al. Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets[J]. J Virology, 2010, 84:10366-10374. [8]Lin SC, Huang MH, Tsou PC, et al. Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines[J]. PLoS One, 2011, 6:e20052. doi: 10.1371/journal.pone.0020052. [9]Cornelissen LA, de Vries RP, de Boer-Luijtze EA, et al. A single immunization with soluble recombinant trimeric hemagglutinin protects chickens against highly pathogenic avian influenza virus H5N1[J]. PLoS One, 2010, 5:1-9. [10]Khurana S, Wu J, Verma N, et al. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans[J]. J Virol, 2011, 85:10945-10954. [11]Correia R, Meneses L, Richheimer C, et al. Improved storage of influenza HA-VLPs using a trehalose-glycerol natural deep eutectic solvent system[J]. Vaccine, 2021, 39:3279-3286. [12]Wang K, Holtz KM, Anderson K, et al. Expression and purification of an influenza hemagglutinin-one step closer to a recombinant protein-based influenza vaccine[J]. Vaccine, 2006, 24:2176-2185. [13]Weldon WC, Wang BZ, Martin MP, et al. Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin[J]. PLoS One, 2010, 5:e12466. doi: 10.1371/journal.pone.0012466 [14]施金荣, 杨晓明, 杜慧, 等. H5N1亚型禽流感病毒样颗粒的构建及鉴定[J]. 中国生物制品学杂志, 2013, 26:145-154. [15]Cai M, Gan P, Hu X, et al. Protective effect of bivalent H1N1 and H3N2 VLP vaccines against Eurasian avian-like H1N1 and recent human-like H3N2 influenza viruses in a mouse model[J]. Vet Microbiology, 2022, 266:109370-109379. |